The abstract is read at the publisher; the summary is JClub's.
Oral ruvonoflast (225 mg twice daily) in high-risk participants with hsCRP ≥2.5 mg/L and BMI 30–40 kg/m² reduced hsCRP by 82.2% at Day 28 versus 37.2% with placebo.
- Why it matters: Residual inflammatory risk in people with high atherosclerotic cardiovascular disease risk remains an unmet target, and NLRP3 inflammasome activity is linked to noncommunicable disease inflammation.
- What they did: In a double-blind Phase 1b trial, 40 participants received ruvonoflast and 23 received placebo while both groups followed a 2,000 kcal/day diet; hsCRP change at Day 28 was the primary Bayesian endpoint.
- The result: hsCRP fell significantly from Day 3 and returned to baseline 7 days after stopping; interleukin-6 and fibrinogen also decreased at Day 28, with similar serious adverse events but more discontinuations from transient reversible events on ruvonoflast.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.